Dupilumab Skin Barrier Function Study in Atopic Dermatitis
NCT04447417
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
52
Enrollment
INDUSTRY
Sponsor class
Conditions
Atopic Dermatitis
Interventions
DRUG:
Dupilumab SAR231893
Sponsor
Sanofi
Collaborators
[object Object]